Talis Biomedical (TLIS) Institutional Ownership $1.70 +0.20 (+13.33%) As of 09/4/2025 01:55 PM Eastern Add Compare Share Share Ownership Stock AnalysisChartCompetitorsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Talis Biomedical (NASDAQ:TLIS)CurrentInstitutional OwnershipPercentage43.77%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$381.02KNumber ofInstitutional Sellers(last 12 months)0 Get TLIS Insider Trade Alerts Want to know when executives and insiders are buying or selling Talis Biomedical stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data TLIS Institutional Buying and Selling by Quarter Talis Biomedical Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/5/2024 BML Capital Management LLC248,702$460K0.3%+481.9%13.665% 1/30/2024 BML Capital Management LLC42,743$318K0.2%N/A2.349% 12/6/2023 Citigroup Inc.5,267$30K0.0%N/A0.289% 5/17/2022Greenlight Capital Inc.2,235,783$3.15M0.2%+42.5%8.399% 5/9/2022 Qube Research & Technologies Ltd47,467$67K0.0%-19.8%0.178% 2/14/2022Greenlight Capital Inc.1,569,300$6.29M0.4%N/A5.969% 2/10/2022 Qube Research & Technologies Ltd59,161$237K0.0%+153.9%0.225% 2/4/2022 Mercer Global Advisors Inc. ADV11,035$44K0.0%-44.9%0.042% 2/1/2022 Qube Research & Technologies Ltd59,161$237K0.0%+153.9%0.225% 11/18/2021 Personal CFO Solutions LLC17,000$106K0.0%N/A0.065% Get the Latest News and Ratings for TLIS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Talis Biomedical and its competitors with MarketBeat's FREE daily newsletter. 11/17/2021 ArrowMark Colorado Holdings LLC5,893,876$36.84M0.3%+0.4%22.420% 11/12/2021 Geode Capital Management LLC302,968$1.89M0.0%+17.4%1.179% 11/9/2021BlackRock Inc.813,137$5.08M0.0%+0.7%3.165% 11/4/2021 Deutsche Bank AG15,007$94K0.0%+85.9%0.058% 9/3/2021Parametric Portfolio Associates LLC50,496$557K0.0%+21.3%0.197% 8/25/2021 Marshall Wace LLP11,326$125K0.0%-80.2%0.044% 8/17/2021 ArrowMark Colorado Holdings LLC5,871,925$32.69M0.2%-2.2%22.856% 8/16/2021 Cubist Systematic Strategies LLC22,920$253K0.0%N/A0.089% 8/16/2021 Redmile Group LLC363,849$4.01M0.1%-9.0%1.416% 8/16/2021 Alyeska Investment Group L.P.100,000$1.10M0.0%+100.0%0.389% 8/16/2021 Morgan Stanley442,250$4.88M0.0%+2,458.6%1.721% 8/16/2021 Charles Schwab Investment Management Inc.95,996$1.06M0.0%+2.5%0.374% 8/16/2021 State Street Corp205,925$2.27M0.0%+40.0%0.802% 8/16/2021Nuveen Asset Management LLC40,060$442K0.0%+87.1%0.156% 8/16/2021 Federated Hermes Inc.15,000$165K0.0%-98.5%0.058% 8/16/2021 Marshall Wace LLP11,326$125K0.0%-80.2%0.044% 8/13/2021 Geode Capital Management LLC258,043$2.85M0.0%+11.2%1.006% 8/13/2021 Vanguard Group Inc.544,906$6.01M0.0%+39.7%2.125% 8/12/2021 JPMorgan Chase & Co.42,230$466K0.0%-73.4%0.165% 8/11/2021 Bank of New York Mellon Corp84,983$938K0.0%+6.3%0.331% 8/11/2021BlackRock Inc.807,299$8.90M0.0%+11.8%3.149% 8/10/2021 Nicholas Investment Partners LP1,071,315$11.82M0.7%-2.7%4.179% 8/5/2021 Rhumbline Advisers12,976$143K0.0%N/A0.051% 8/2/2021 New York State Common Retirement Fund38,414$424K0.0%-2.9%0.150% (Data available from 1/1/2016 forward) TLIS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of TLIS shares? During the previous two years, the following institutional investors and hedge funds held shares of Talis Biomedical shares: BML Capital Management LLC ($460K), Citigroup Inc. ($30K).Learn more on Talis Biomedical's institutional investors. What percentage of Talis Biomedical's stock is owned by institutional investors? 43.77% of Talis Biomedical's stock is owned by institutional investors. Learn more on TLIS's institutional investor holdings. Which institutional investors have been buying Talis Biomedical's stock? The following institutional investors have purchased Talis Biomedical's stock in the last 24 months: BML Capital Management LLC ($248.70K), and Citigroup Inc. ($5.27K). How much institutional buying is happening at Talis Biomedical? Institutional investors have bought a total of 205,959 shares in the last 24 months. This purchase volume represents approximately $381.02K in transactions. Related Companies ASTC Major Shareholders TT Major Shareholders KEYS Major Shareholders VLTO Major Shareholders TER Major Shareholders FTV Major Shareholders RVTY Major Shareholders AVTR Major Shareholders NVMI Major Shareholders VNT Major Shareholders This page (NASDAQ:TLIS) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talis Biomedical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talis Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
